RNA Blood Testing for Rapid Stroke Subtype Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating ischemic and hemorrhagic strokes are time-consuming and often delay the administration of tissue plasminogen activator (tPA), which is contraindicated for hemorrhagic strokes, leading to untreated patients missing the optimal treatment window.
Innovation Solution
An RNA-based method that involves extracting RNA from a blood sample, generating a transcriptome profile, and analyzing it to determine whether the stroke is ischemic or hemorrhagic, enabling timely tPA therapy decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CT imaging and radiologist review are performed to exclude hemorrhagic stroke before tPA administration, then patient safety is improved, but treatment time is significantly delayed
Solution Approach 1:
The patent performs stroke subtype differentiation through RNA biomarker analysis at the point of care, before the patient leaves the emergency department. This preliminary action provides the necessary diagnostic information to safely administer tPA without requiring delayed radiologist review, thus resolving the contradiction between ensuring patient safety and minimizing treatment delay
Solution Approach 2:
The patent introduces a point-of-care testing device as an intermediary between clinical presentation and tPA decision-making. This device rapidly analyzes RNA biomarkers in whole blood to differentiate stroke subtypes, serving as a mediator that provides safe tPA eligibility determination without requiring traditional CT imaging and radiologist interpretation, thereby eliminating the time delay while maintaining safety
2Measurement precision
If traditional CT imaging and radiologist review procedures are used, then accurate stroke subtype differentiation is achieved, but the optimal treatment window is missed for many patients
Solution Approach 1:
The patent replaces the mechanical system of CT imaging, radiologist interpretation, and report generation with a point-of-care testing device that directly analyzes RNA biomarkers in whole blood. This substitution maintains measurement precision for stroke subtype differentiation while dramatically increasing productivity by providing results at the point of care within minutes, enabling timely tPA administration within the optimal treatment window
Solution Approach 2:
The patent changes the diagnostic parameter from anatomical imaging (CT scans requiring radiologist interpretation) to molecular biomarker analysis (RNA expression profiles in whole blood). This parameter change enables rapid, accurate stroke subtype differentiation at the point of care, simultaneously improving both measurement precision and treatment delivery speed by eliminating the time-consuming imaging and interpretation workflow
3Productivity
If tPA is administered without rapid stroke subtype differentiation, then treatment access is improved, but hemorrhagic stroke patients receive contraindicated treatment
Solution Approach 1:
The patent performs rapid RNA biomarker analysis at the point of care to preliminarily determine stroke subtype before tPA administration. This preliminary action identifies hemorrhagic stroke patients who would be harmed by tPA, enabling safe treatment access by preventing contraindicated treatment while maintaining high productivity in the tPA decision-making process
Data Source
AI summary
A method for screening stroke suspects, comprising the steps of extracting RNA from a blood sample of a stroke suspect, generating a transcriptome profile of the stroke suspect based on the RNA extracted from the blood sample, analyzing the transcriptome profile of the stroke suspect to generate a report indicating whether the stroke suspect suffered a stroke and, in the case that the stroke suspect suffered a stroke, whether the stroke is an ischemic stroke or a hemorrhagic stroke.